Quest Diagnostics (DGX) Tops Q4 EPS by 16c; Offers 2022 Guidance
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Price: $235.50 -0.69%
EPS Growth %: +10.0%
Financial Fact:
Cost of services: 1.16B
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +10.0%
Financial Fact:
Cost of services: 1.16B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $3.33, $0.16 better than the analyst estimate of $3.17. Revenue for the quarter came in at $2.67 billion versus the consensus estimate of $2.66 billion.
GUIDANCE:
Quest Diagnostics sees FY2022 EPS of $8.65-$9.35, versus the consensus of $8.71. Quest Diagnostics sees FY2022 revenue of $9-9.5 billion, versus the consensus of $9.21 billion.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Quest Diagnostics (DGX) PT Raised to $245 at UBS
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- BMO Capital Starts Abercrombie & Fitch (anf) at Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
